

Welcome to your CDP Water Security Questionnaire 2020

W0. Introduction

W0.1

(W0.1) Give a general description of and introduction to your organization.

Pfizer applies science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. Pfizer has a number of key sustainability priorities that we believe have the potential to make a significant positive environmental and social impact by conserving natural resources, reducing waste and increasing access of our products to patients. Key priorities include:

- Reducing the greenhouse gas (GHG) emissions associated with our operations, including application of engineering and sustainability innovations to building management and construction;
- Decreasing waste generated from our operations through a multifaceted approach including source reduction, waste minimization, and recycling improvements, and finding markets/outlets to reuse materials we cannot reduce or recycle ourselves;
- Reducing water withdrawal associated with our operations and being good stewards of the water we use;
- Further reducing the environmental footprint of our products through improvements in process design;
- Encouraging key suppliers to reduce GHG emissions, water, and waste disposed;
- Providing access to medicines and vaccines especially in underserved populations; and
- Leveraging our resources to help support strengthening of healthcare systems in low- and middle-income countries

Further information can be found at www.Pfizer.com or through Pfizer's social media including Twitter [@Pfizer](https://twitter.com/Pfizer) and [@Pfizer News](https://twitter.com/PfizerNews), [LinkedIn](https://www.linkedin.com/company/pfizer), [YouTube](https://www.youtube.com/pfizer) and [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

Disclosure Notice: The information contained in this response is as of Aug 26, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this response as the result of new information or future events or developments. This response contains forward-looking information about potential impacts of climate change to Pfizer, including regulatory, physical and business risks and opportunities, and information related to climate change strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such

risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing, or implementation of new regulations; projected financial impact and management cost; and projected performance on climate change related goals. Pfizer's past performance in attaining reductions in greenhouse gas emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer's Form 10-K for the fiscal year ended December 31, 2019, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at www.sec.gov and www.pfizer.com.

W0.2

(W0.2) State the start and end date of the year for which you are reporting data.

	Start date	End date
Reporting year	January 1, 2019	December 31, 2019

W0.3

(W0.3) Select the countries/areas for which you will be supplying data.

Algeria
 Argentina
 Australia
 Austria
 Belgium
 Brazil
 Canada
 Chile
 China
 Colombia
 Croatia
 Denmark
 Ecuador
 Egypt
 Finland
 France
 Germany
 Greece
 India
 Indonesia
 Ireland
 Italy
 Japan
 Lebanon
 Mexico
 Morocco

Netherlands
Pakistan
Portugal
Puerto Rico
Republic of Korea
Romania
Russian Federation
Saudi Arabia
Senegal
Singapore
South Africa
Spain
Sweden
Switzerland
Taiwan, Greater China
Tunisia
Turkey
United Kingdom of Great Britain and Northern Ireland
United States of America
Venezuela (Bolivarian Republic of)

W0.4

(W0.4) Select the currency used for all financial information disclosed throughout your response.

USD

W0.5

(W0.5) Select the option that best describes the reporting boundary for companies, entities, or groups for which water impacts on your business are being reported.

Companies, entities or groups over which operational control is exercised

W0.6

(W0.6) Within this boundary, are there any geographies, facilities, water aspects, or other exclusions from your disclosure?

No

W1. Current state

W1.1

(W1.1) Rate the importance (current and future) of water quality and water quantity to the success of your business.

	Direct use importance rating	Indirect use importance rating	Please explain
Sufficient amounts of good quality freshwater available for use	Vital	Important	<p>Direct: As a manufacturer of biopharmaceutical healthcare products, water quality and water quantity are vital to our work. All water used for manufacturing purposes must first meet potable drinking water requirements and is treated to meet product quality standards if necessary. The water is then further treated and purified to meet applicable pharmacopeial water quality regulatory requirements specific to the process. Major onsite uses of water include drug production and cleaning. We also use some water and energy to heat and cool our manufacturing processes. We do not anticipate our direct reliance on quality freshwater to change in the foreseeable future.</p> <p>Indirect: Our major suppliers include manufacturers of active pharmaceutical ingredients, prescription drug products, and product packaging. Since our suppliers are working in our value chain, many of them are also reliant on adequate quantities of good quality water to produce products. Because water availability and quality are critical to our and our suppliers' manufacturing processes, we do not anticipate our indirect reliance on quality freshwater to change in the foreseeable future.</p>
Sufficient amounts of recycled, brackish and/or produced water available for use	Neutral	Neutral	<p>Direct: Although a small number of our manufacturing sites utilize recycled water in industrial applications and for landscaping/irrigation, non-freshwater cannot be used in our manufacturing processes for quality reasons and is therefore not critical to our operations.</p> <p>Indirect: Our key suppliers' operations are similar to ours and are subject to similar quality requirements and as such are not reliant on non-freshwater for their operations.</p> <p>Because recycled water cannot be used in pharmaceutical manufacturing, we do not anticipate an increase in either our or our suppliers' reliance on non-freshwater in the foreseeable future.</p>

W1.2

(W1.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?

	% of sites/facilities/operations	Please explain
Water withdrawals – total volumes	100%	Pfizer collects and reports water withdrawal for all locations where we maintain operational control. Water withdrawal volumes are measured and monitored at the site level and are reported centrally via our global environmental reporting system (Enablon). Manufacturing and Research sites provide monthly withdrawal data (with a few exceptions where water data is only available quarterly). Office locations report withdrawal annually. Withdrawal data for small sources (Research and Development facilities less than 50,000 sq ft and Logistics/Commercial facilities less than 100,000 sq ft) may be estimated.
Water withdrawals – volumes by source	100%	Pfizer collects and reports water withdrawal for all locations where we maintain operational control. Water withdrawal volumes are measured and monitored at the site level and are reported centrally via our Enablon system. Manufacturing and Research sites provide monthly withdrawal data (with a few exceptions where water data is only available quarterly). Office locations report withdrawal annually. Withdrawal data for small sources (Research and Development facilities less than 50,000 sq ft and Logistics/Commercial facilities less than 100,000 sq ft) may be estimated.
Water withdrawals quality	76-99	Water quality is monitored by sites as required by regulation (local potable water standards) and as necessary to ensure conformance with quality standards for manufacturing. Water is purified as necessary to support manufacturing and research operations.
Water discharges – total volumes	100%	Water discharge volumes are monitored by all sites under Pfizer's operational control and are reported centrally by discharge destination via the Enablon system. Manufacturing and Research locations report monthly discharge volumes. Office locations report wastewater discharge annually. Discharge data for small

		sources (Research and Development facilities less than 50,000 sq ft and Logistics/Commercial facilities less than 100,000 sq ft) may be estimated.
Water discharges – volumes by destination	76-99	Water discharge volumes are monitored by all sites under Pfizer's operational control and are reported centrally by discharge destination via the Enablon system. Manufacturing and Research locations report monthly discharge volumes. Office locations report wastewater discharge annually. Discharge data for small sources (Research and Development facilities less than 50,000 sq ft and Logistics/Commercial facilities less than 100,000 sq ft) may be estimated.
Water discharges – volumes by treatment method	76-99	Pfizer does not require facilities to report water discharge by treatment method, however, each site constantly monitors its treatment processes and measures discharge volumes. Discharge requirements are not consistent from location to location.
Water discharge quality – by standard effluent parameters	76-99	Pfizer requires sites to monitor wastewater discharge quality and meet all applicable permit and/or regulatory requirements. Sites must also limit releases by meeting the expected internal environmental standards for active pharmaceutical ingredient concentrations in wastewater. This data is maintained by the site but is not collected at the corporate level. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits.
Water discharge quality – temperature	76-99	Pfizer requires sites to monitor wastewater discharge quality and meet all applicable permit and/or regulatory requirements. This data is maintained by the site but is not collected at the corporate level. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits.
Water consumption – total volume	100%	Water withdrawal and discharge volumes are monitored by all sites under Pfizer's operational control and are reported centrally via the Enablon

		system (monthly for manufacturing and research sites, annually for offices). This data is used to calculate water consumption.
Water recycled/reused	76-99	Recycled water volumes are monitored by all sites under Pfizer's operational control and are reported centrally via our Enablon system. Manufacturing and Research sites report recycled water volumes monthly. Pfizer currently does not have any office locations that recycle or reuse water.
The provision of fully-functioning, safely managed WASH services to all workers	76-99	Pfizer's Global EHS Standards require all facilities to provide safe, fully functioning WASH services for all employees. Compliance is monitored through our internal audit program.

W1.2b

(W1.2b) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, and how do these volumes compare to the previous reporting year?

	Volume (megaliters/year)	Comparison with previous reporting year	Please explain
Total withdrawals	36,296	Higher	In 2019, Pfizer's total water withdrawal increased by 1.5% compared to 2018 due to increased production. Water withdrawal is expected to increase over the next five years due to further increases in production.
Total discharges	32,606	Higher	Pfizer's wastewater discharge increased by 3% compared to 2018, primarily due to increased use of non-contact cooling water to support production increases.
Total consumption	3,690	Lower	Pfizer's water consumption in 2019 was 11.5% lower than in 2018.

W1.2d

(W1.2d) Indicate whether water is withdrawn from areas with water stress and provide the proportion.

Withdrawals are from areas with water stress	% withdrawn from areas	Comparison with previous reporting year	Identification tool	Please explain

		with water stress			
Row 1	Yes	76-99	Higher	WRI Aqueduct	Pfizer entered site geolocation data into the WRI Aqueduct tool to identify sites located in areas with water stress. Pfizer's water withdrawal in these areas increased 5% compared to 2018. We continue to improve water management at all Pfizer sites, including those in water-stressed areas, and our medium and large sites are required to maintain environmental sustainability master plans which identify short- and medium-term projects to reduce water withdrawal.

W1.2h

(W1.2h) Provide total water withdrawal data by source.

	Relevance	Volume (megaliters/year)	Comparison with previous reporting year	Please explain
Fresh surface water, including rainwater, water from wetlands, rivers, and lakes	Relevant	872	Lower	Pfizer uses of surface water and rainwater is primarily for non-contact cooling. Pfizer's use of surface water increased 23% compared to 2018 as a result of increased production at our Strangnas, Sweden facility. Rainwater use increased 11.5% compared to 2018.
Brackish surface water/Seawater	Not relevant			Pfizer implemented improvements in 2016 which eliminated the use of brackish surface water for one-pass cooling at our Groton, CT facility. We do not anticipate using brackish surface water in our

				operations in the next few years.
Groundwater – renewable	Relevant	25,735	About the same	Pfizer's Kalamazoo, Michigan site is the company's largest user of groundwater. Groundwater is used in manufacturing operations as well as for non-contact cooling. Overall, Pfizer's groundwater withdrawal increased 2.7% compared to 2018 due to increased production.
Groundwater – non-renewable	Not relevant			Pfizer's groundwater use is limited to renewable water from shallow wells. Pfizer sites do not withdraw water from non-renewable groundwater sources, and we do not anticipate doing so in the future.
Produced/Entrained water	Not relevant			Pfizer does not use produced water in operations. Given our need for high quality and very pure water, it is expensive and energy intensive to source produced water. Going forward, we do not anticipate using produced water in our operations.
Third party sources	Relevant	9,690	Lower	Pfizer's use of municipal water decreased 3% compared to 2018 due to the closure of two manufacturing facilities and the implementation of water conservation projects. For example, our Little Island, Ireland site completed a project to replace single-pass non-contact cooling water with a closed loop system, reducing the site's water withdrawal nearly 58%

				<p>compared to 2018. We expect to exceed our 2020 public water reduction goal of reducing water withdrawal (excluding non-contact cooling water) by 5% compared to a 2012 baseline. Going forward, we anticipate some near-term increases in water consumption due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects.</p>
--	--	--	--	--

W1.2i

(W1.2i) Provide total water discharge data by destination.

	Relevance	Volume (megaliters/year)	Comparison with previous reporting year	Please explain
Fresh surface water	Relevant	22,166	Higher	<p>Pfizer's discharge to surface water increased 4.4% compared to 2018 due primarily to an increase in non-contact cooling water use. We are on track to exceed our 2020 public water reduction goal of reducing water withdrawal (excluding non-contact cooling water) by 5% compared to a 2012 baseline. Going forward, we anticipate some near-term increases in water withdrawal and discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects.</p>

Brackish surface water/seawater	Relevant	1,004	Higher	Pfizer's discharge to saltwater increased 7.6% compared to 2018.
Groundwater	Not relevant			Pfizer does not discharge to groundwater.
Third-party destinations	Relevant	9,315	About the same	Pfizer's discharge to third party (municipal) wastewater treatment facilities decreased 1.3% compared to 2018. We do not discharge any wastewater to other organizations for further use. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects.

W1.4

(W1.4) Do you engage with your value chain on water-related issues?

Yes, our suppliers

Yes, our customers or other value chain partners

W1.4a

(W1.4a) What proportion of suppliers do you request to report on their water use, risks and/or management information and what proportion of your procurement spend does this represent?

Row 1

% of suppliers by number

1-25

% of total procurement spend

26-50

Rationale for this coverage

Leveraging published industry and company life cycle assessments (LCA), Pfizer identified the leading suppliers in the major product categories accounting for largest supply chain environmental impacts: 45% manufacturing operations; 25% raw material suppliers; 25% packaging materials; and 1% transportation vendors. There was a clear

delineation that working with the top 150 suppliers in these categories would maximize our impact.

Impact of the engagement and measures of success

In 2015 Pfizer Executive Leadership endorsed a public supplier sustainability goal targeting all key suppliers to track GHG emissions, waste and water and 90% to institute reduction goals by 2020. The Pfizer Annual Review publishes results of the annual supplier survey which indicates progress year on year. In 2019, 90% of suppliers reported managing their environmental impact (up 6% from prior year) and 53% have established reduction goals. Pfizer and Ecodesk, our partner that administers and manages the survey, engage with these suppliers regularly to ensure participation, provide support as needed in reporting and to help them understand our expectations and their results. Pfizer uses the survey results to report progress on our public goals and also to provide feedback to suppliers.

Comment

Pfizer has been leading an industry effort to standardize sustainability survey questions to suppliers through the Pharmaceutical Supply Chain initiative (PSCI). As suppliers deliver services to a number of pharmaceutical companies, the coordination will ease the burden on suppliers and has already increased supplier participation rates.

W1.4b

(W1.4b) Provide details of any other water-related supplier engagement activity.

Type of engagement

Innovation & collaboration

Details of engagement

Encourage/incentivize innovation to reduce water impacts in products and services

% of suppliers by number

1-25

% of total procurement spend

26-50

Rationale for the coverage of your engagement

Pfizer is an original member of the Pharmaceutical Supply Chain Initiative (PSCI), a collaboration of now 44 pharmaceutical companies whose purpose is to define, implement and champion responsible supply chain practices. PSCI has established Principles that articulate the members' expectations for suppliers to operate in an environmentally responsible and efficient manner to minimize adverse impacts on the environment, including having systems in place to ensure the safe handling of wastewater discharge and to prevent and mitigate releases to the environment. Pfizer has incorporated the PSCI Principles into our supply agreement templates and our Supplier Conduct Principles.

Impact of the engagement and measures of success

PSCI members work together to audit supplier compliance with the Principles and to build supplier capabilities through annual conferences, webinars and the provision of a resource library. In 2019 PSCI conducted two large-scale supplier conferences reaching over 400 delegates in India and China, important sourcing regions for many member companies, including several sessions led by Pfizer colleagues. PSCI recently launched a Supplier Community Platform that provides resources to help suppliers advance responsible supply chain practices.

Comment

PSCI engaged with Nordea, a sustainable investment firm that investigated and reported on water pollution allegedly associated with pharmaceutical manufacturing operations in India in 2015-2016, to facilitate positive change. PSCI's efforts were acknowledged by Nordea as a "very positive step in the right direction". PSCI will continue to work with suppliers to ensure appropriate management of wastewater and seeks to partner with like-minded organizations to improve wastewater treatment.

W1.4c

(W1.4c) What is your organization's rationale and strategy for prioritizing engagements with customers or other partners in its value chain?

Pfizer works closely with our customer success team to address sustainability and water requests from our customers. As a founding member of the AMR (Antimicrobial Resistance) Industry Alliance Manufacturing Group, Pfizer is partnering with peer companies, many of whom are our customers, and key stakeholders to establish and implement a common framework for managing antibiotic discharge.

W2. Business impacts

W2.1

(W2.1) Has your organization experienced any detrimental water-related impacts?

No

W2.2

(W2.2) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?

Yes, fines, enforcement orders or other penalties but none that are considered as significant

W2.2a

(W2.2a) Provide the total number and financial value of all water-related fines.

Row 1

Total number of fines

2

Total value of fines

820

% of total facilities/operations associated

2

Number of fines compared to previous reporting year

Higher

Comment

Pfizer received two minor fines for wastewater permit limit exceedances at its Sanford, North Carolina and Tuas, Singapore facilities.

W3. Procedures

W3.3

(W3.3) Does your organization undertake a water-related risk assessment?

Yes, water-related risks are assessed

W3.3a

(W3.3a) Select the options that best describe your procedures for identifying and assessing water-related risks.

Direct operations

Coverage

Full

Risk assessment procedure

Water risks are assessed as part of an enterprise risk management framework

Frequency of assessment

Annually

How far into the future are risks considered?

More than 6 years

Type of tools and methods used

Tools on the market
International methodologies
Other

Tools and methods used

WRI Aqueduct
IPCC Climate Change Projections
Internal company methods

External consultants
Other, please specify
Swiss Re CatNet; FEMA Flood Zone Maps

Comment

Multiple tools are used at the corporate and site levels to assess water-related risks. Site-specific surveys are conducted to assess site operations and water management practices. In addition, Pfizer has a detailed risk review process that assesses short, medium and long-term acute and chronic water risks. Each Pfizer site is required to maintain a business continuity program that assesses local municipality risks and other supply risks and to address these risks in site-specific business continuity strategy plans.

Supply chain

Coverage

Partial

Risk assessment procedure

Water risks are assessed as part of an enterprise risk management framework

Frequency of assessment

Annually

How far into the future are risks considered?

More than 6 years

Type of tools and methods used

Tools on the market
International methodologies
Other

Tools and methods used

IPCC Climate Change Projections
Internal company methods
Other, please specify
Swiss Re CatNet; FEMA Flood Zone Maps

Comment

Pfizer has a detailed risk review process that assesses short, medium and long-term acute and chronic water risks for our supply chain. To date we have completed assessments for more than 5,000 contract manufacturers and material suppliers. In addition, Pfizer engages approximately 150 key suppliers in an annual survey that asks them to provide information on water scarcity assessments and risk mitigation plans as well as programs to control Active Pharmaceutical Ingredients (API) in wastewater. Pfizer's supplier landing page encourages suppliers to utilize the WRI Aqueduct Tool to assess water risk.

Other stages of the value chain

Coverage

Partial

Risk assessment procedure

Water risks are assessed as a standalone issue

Frequency of assessment

Annually

How far into the future are risks considered?

More than 6 years

Type of tools and methods used

Other

Tools and methods used

Internal company methods

External consultants

Comment

Pfizer has a risk assessment program to evaluate potential risks associated with pharmaceuticals in the environment, including water systems. Pfizer has fully adopted the AMR Industry Alliance "Common Manufacturing Framework" and has verified through audit that greater than 90% of our internal sites meet the framework. The expectations of the framework have been conveyed to all our antibiotic suppliers and assessments have been completed against the framework for greater than 80% of these suppliers.

W3.3b**(W3.3b) Which of the following contextual issues are considered in your organization's water-related risk assessments?**

	Relevance & inclusion	Please explain
Water availability at a basin/catchment level	Relevant, always included	A reliable water supply is critical to Pfizer's operations. Pfizer uses the WRI Aqueduct tool and the WBCSD Global Water Tool to identify sites in water scarce regions. Sites identified through these tools are required to complete a follow-up risk assessment survey and to maintain business continuity plans that address potential water shortages.
Water quality at a basin/catchment level	Relevant, always included	Water quality is critical for the manufacturing of pharmaceuticals. Pfizer sites that have identified potential water quality concerns are required to complete a follow-up risk assessment survey and to maintain business continuity plans that address potential shortages of suitable water. Pfizer continues to manage the stewardship of issues associated with pharmaceuticals in the environment, with antimicrobial resistance currently prioritized. Pfizer has a

		<p>risk assessment program to evaluate potential risks associated with pharmaceuticals in the environment, including water systems. Pfizer has fully adopted the AMR Industry Alliance "Common Manufacturing Framework" and has verified through audit that greater than 90% of our internal sites meet the framework. The expectations of the framework have been conveyed to all our antibiotic suppliers and assessments have been completed against the framework for greater than 80% of these suppliers.</p>
Stakeholder conflicts concerning water resources at a basin/catchment level	Relevant, always included	<p>Where required, withdrawal (supply) permits are maintained. All our facilities are periodically audited against local regulatory and internal standards, including those related to water. EHS teams at sites track local water issues. Local stakeholder issues concerning water or other critical utilities are factored into site business continuity planning.</p>
Implications of water on your key commodities/raw materials	Relevant, always included	<p>A reliable supply of potable drinking water is critical to many of our suppliers. Pfizer requests that key suppliers complete assessments of water risk, including the effectiveness of controls to prevent discharges of antimicrobials to the environment. We have completed physical risk assessments to assess water scarcity for over 5,000 of our contract manufacturers and material suppliers. In addition, we survey approximately 150 of these suppliers annually using the PSCI Survey administered through the Ecodesk platform.</p>
Water-related regulatory frameworks	Relevant, always included	<p>Where required, withdrawal and discharge permits are maintained by our sites. All our facilities are periodically audited against local regulatory and internal standards, including those related to water. EHS teams at sites track issues related to water. Changes in regulatory and/or permit requirements are factored into site risk assessments. For example, the country of Singapore continues to monitor industrial water use closely and has been increasing the requirements for industry to use NEWater (recycled water) instead of fresh water for operations. This water does not meet quality requirements for use in pharmaceutical manufacturing and as such the site has been required to closely monitor water use and identify and implement water conservation projects to ensure adequate fresh water supplies for manufacturing.</p>
Status of ecosystems and habitats	Relevant, sometimes included	<p>Included where relevant and identified through local knowledge and engagement with local regulators. Ongoing and future risks managed primarily through adherence to local regulatory requirements and permits.</p>

Access to fully-functioning, safely managed WASH services for all employees	Relevant, always included	Pfizer's Global EHS Standards require all facilities to provide safe, fully functioning WASH services for all employees. Compliance is monitored through our internal audit program. Pfizer has extended the provision of WASH services to employees' families and even the community in times of need. For example, the Chennai, India region is currently experiencing water shortages as a result of dry weather. This, combined with a poor water supply infrastructure, requires Pfizer to rely on private water suppliers to support our research and commercial sites located in the region. Pfizer sites in this region provide bottled water for drinking and hygienic purposes to our employees and their families.
Other contextual issues, please specify	Not considered	We do not consider other contextual issues at this time.

W3.3c

(W3.3c) Which of the following stakeholders are considered in your organization's water-related risk assessments?

	Relevance & inclusion	Please explain
Customers	Relevant, always included	Our customers rely upon access to clean drinking water to use our products. Actions to reduce improper disposal of expired or unwanted prescription and non-prescription medicines helps protect water supplies. Through education and awareness programs, we work together with regulatory agencies, the broader healthcare community, and the public to better understand the potential impacts associated with the improper disposal of unused medicines. Pfizer is actively partnering with other pharmaceutical companies and government agencies to support proper unused medicine disposal, supporting voluntary community collection programs involving law enforcement and educating patients and families on proper disposal and has taken key leadership roles in our industry's efforts to comply with mandatory unused medicine collection and disposal requirements in the U.S.
Employees	Relevant, always included	Pfizer maintains reliable sources of potable water at its facilities. In areas where water availability may be impacted by drought or severe weather events, sites have controls in place to ensure access to water for our employees. Our sites in India supply bottled water for employee consumption, cooking and hygiene purposes. Our employees also play a significant role in reducing our water footprint, participating in site environmental

		sustainability initiatives and identifying and implementing water conservation projects.
Investors	Relevant, always included	Investors and public health NGOs have called for increased scrutiny of the suppliers of antibiotics to assess wastewater management practices as an additional measure against antimicrobial resistance (AMR). With a large anti-infective portfolio Pfizer assesses and manages environmental risks associated with the supply of antimicrobial products (potentially related to AMR). In 2016, Pfizer and 12 industry partners released a comprehensive plan of action that includes four key environmental commitments we pledge to deliver by 2020 to reduce the rising incidence of AMR. Since then many more companies in the industry have joined the Alliance. The Alliance has delivered on its commitments, in some cases ahead of schedule. For more information see https://www.amrindustryalliance.org/ . Pfizer publicly discloses our management of water-related risks, including scarcity and pharmaceuticals in the environment, through CDP and on our public website.
Local communities	Relevant, always included	Pfizer recognizes the importance of ensuring that our water usage does not negatively affect the communities where we operate by diminishing the supplies of clean water or degrading the quality of that water. Pfizer requires its facilities worldwide to quantify water use, report performance against reduction targets, and support community efforts during drought conditions.
NGOs	Relevant, always included	Investors and public health NGOs have called for increased scrutiny of the suppliers of antibiotics to assess wastewater management practices as an additional measure against antimicrobial resistance. With a large anti-infective portfolio Pfizer continues to assess risk and manage stewardship of issues associated with antimicrobial resistance (AMR). In 2016, Pfizer and 12 industry partners released a comprehensive plan of action that outlines the four key commitments we pledge to deliver by 2020 to reduce the rising incidence of AMR. Since then many more companies in the industry have joined the Alliance. The Alliance has delivered on its commitments, in some cases ahead of schedule. For more information see https://www.amrindustryalliance.org/ .
Other water users at a basin/catchment level	Relevant, sometimes included	Water use by Pfizer and other local water users is small compared to available supply. Pfizer locations that provide wastewater treatment for other local water users factor these users into their risk assessments.
Regulators	Relevant, always included	Our sites track water-related regulatory matters. At the corporate level, risks associated with compliance and potential regulatory changes are considered in our Operational Risk Evaluation

		process. Through our trade associations, Pfizer engages with EU regulators on issues of PIE to adopt sound, reasonably practicable regulations for the Water Framework Directive.
River basin management authorities	Not relevant, explanation provided	Pfizer's water withdrawal, consumption and discharges are small in relation to river basin supply. Accordingly, there is no apparent benefit to including river basin authorities in our risk assessments at this time and we do not anticipate any changes that would cause these stakeholders to become relevant in the foreseeable future.
Statutory special interest groups at a local level	Not relevant, explanation provided	The need to interact with and consider these stakeholders would be done on a case-by-case basis at the local site level and at present is not relevant. It is difficult to anticipate if these stakeholders may become relevant in the future, but it is a reasonable possibility, particularly in areas of increasing water scarcity and/or declining water quality.
Suppliers	Relevant, sometimes included	Pfizer has a detailed risk review process that assesses short, medium and long-term acute and chronic water risks for our supply chain. To date we have completed assessments for more than 5,000 contract manufacturers and material suppliers. Pfizer also collects quantitative and qualitative data related to water management programs at its most strategically important 1st and 2nd tier suppliers of active pharmaceutical ingredients, consumer and prescription drug products and product packaging services.
Water utilities at a local level	Relevant, always included	Local stakeholder issues concerning water or other critical utilities are raised to the management level, and risks assessed.
Other stakeholder, please specify	Not considered	Pfizer has not identified other stakeholders for consideration in risk assessments.

W3.3d

(W3.3d) Describe your organization's process for identifying, assessing, and responding to water-related risks within your direct operations and other stages of your value chain.

Pfizer identifies and addresses water-related risk through a three-step annual risk assessment process, our business continuity strategy program and our Operational Risk Evaluation and Review processes.

1) We use the WRI Aqueduct, WBCSD, and IPCC Global Water tools to initially identify water-related risks with the potential to have substantive financial or strategic impact to the business.

2) We perform a site-level assessment of water-related system operations and water program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). As part of

the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations.

3) Subject matter experts conduct an onsite review for sites determined to be at higher risk.

Sites are then mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to have vulnerabilities to water scarcity are required to develop remediation plans and business continuity plans. These assessments are conducted annually or more frequently if there are significant changes to a facility. Information from both of the above processes is then reviewed at the enterprise level through Pfizer's Operational Risk Evaluation process.

Pfizer uses an annual survey to collect information related to our key suppliers' water management programs. In 2019, 80% of these suppliers indicated they have completed assessments of water scarcity and quality and have developed long-term plans for water security as applicable and 91% responded that they have established controls (if applicable) to minimize releases of active pharmaceutical ingredients in wastewater. Pfizer also assesses short, medium and long-term acute and chronic water risks for our supply chain as part of our Business Resilience program and to date have completed assessments for more than 5,000 contract manufacturers and material suppliers.

W4. Risks and opportunities

W4.1

(W4.1) Have you identified any inherent water-related risks with the potential to have a substantive financial or strategic impact on your business?

Yes, both in direct operations and the rest of our value chain

W4.1a

(W4.1a) How does your organization define substantive financial or strategic impact on your business?

For the purposes of this response, Pfizer defines "substantive" water-related risk as any impact that could adversely impact the company's business or financial condition or disrupt, delay or inhibit the supply of products designated as financially critical, medically necessary, and/or medically significant. For risks that can be evaluated financially, Pfizer has applied a threshold of \$100MM for considering a risk substantive in this context. Pfizer applies these criteria when assessing both direct and indirect risks and opportunities. Pfizer also considers areas posing reputational risk to the company.

CDP's phrasing of "substantive" and our response to questions presenting "substantive" risks should not be considered to relate to matters or facts that could be deemed "material" to a

reasonable investor as referred to under U.S. securities laws or similar requirements of other jurisdictions. Investors should refer to disclosures in our Annual Report on Form 10-K ("10-k") and in our other filings with the US Securities and Exchange Commission, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of "material" matters.

W4.1b

(W4.1b) What is the total number of facilities exposed to water risks with the potential to have a substantive financial or strategic impact on your business, and what proportion of your company-wide facilities does this represent?

	Total number of facilities exposed to water risk	% company-wide facilities this represents	Comment
Row 1	1	1-25	Pfizer used the WRI Aqueduct tool and WBCSD Global Water Tool to initially identify water-related risks with the potential to have substantive financial or strategic impact to its business. The sites identified to be potentially at risk were further surveyed using input from tools and consultants including WRI, CERES and WSP. As a result of this evaluation process, Pfizer identified one site as having inherent chronic risk.

W4.1c

(W4.1c) By river basin, what is the number and proportion of facilities exposed to water risks that could have a substantive financial or strategic impact on your business, and what is the potential business impact associated with those facilities?

Country/Area & River basin

Saudi Arabia
 Not known

Number of facilities exposed to water risk

1

% company-wide facilities this represents

1-25

% company's total global revenue that could be affected

Less than 1%

Comment

W4.2

(W4.2) Provide details of identified risks in your direct operations with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.

Country/Area & River basin

Saudi Arabia
Not known

Type of risk & Primary risk driver

Physical
Declining water quality

Primary potential impact

Reduction or disruption in production capacity

Company-specific description

Pfizer's manufacturing facility in Saudi Arabia is located in a government-run industrial park that sources water from the Red Sea. The industrial park's desalination plant has been unable to meet quality and reliability standards required to support our manufacturing operations. As a result, the site relies on water supplied to the site by truck for GMP manufacturing needs and purified water production.

Timeframe

Current up to one year

Magnitude of potential impact

Low

Likelihood

Virtually certain

Are you able to provide a potential financial impact figure?

Yes, a single figure estimate

Potential financial impact figure (currency)

100,000

Potential financial impact figure - minimum (currency)

Potential financial impact figure - maximum (currency)

Explanation of financial impact

Includes costs of water hauling, monitoring and testing. Estimated annual cost based on current spend.

Primary response to risk

Other, please specify

Manage water risks and impacts through business continuity planning

Description of response

Sites in areas where water scarcity has been identified as a potential risk address water availability and quality through their short term and long-term business continuity plans. Where appropriate these sites have established strategies for water sourcing and have increased their ability to acquire and store water from alternative sources. Business continuity plans are reviewed with senior site leadership on a regular/annual basis.

Cost of response

0

Explanation of cost of response

The costs associated with monitoring status and maintaining business continuity programs are relatively low and are integrated into staff costs.

W4.2a

(W4.2a) Provide details of risks identified within your value chain (beyond direct operations) with the potential to have a substantive financial or strategic impact on your business, and your response to those risks.

Country/Area & River basin

India

Other, please specify

Multiple basins

Stage of value chain

Supply chain

Type of risk & Primary risk driver

Reputation & markets

Increased stakeholder concern or negative stakeholder feedback

Primary potential impact

Supply chain disruption

Company-specific description

A number of reports have highlighted concerns about chemical/pharmaceutical pollution (including antibiotics) in water courses in proximity to some chemical/pharmaceutical suppliers in India as well as globally. These reports increased the focus on pharmaceutical manufacturing facilities as a potential contributor to the antimicrobial resistance (AMR) issue. Investors and public health NGOs have called for increased action by antibiotics manufacturers in responsible wastewater management practices as an additional measure against antimicrobial resistance. With a significant anti-infective portfolio Pfizer continues to manage stewardship of issues associated with anti-

microbial resistance globally. In 2016, Pfizer and 12 industry partners released a comprehensive plan of action that outlines the four key commitments we pledge to deliver by 2020 to reduce the rising incidence of AMR. Since then additional companies in the industry have joined the Alliance. The Alliance has delivered on its commitments, in some cases ahead of schedule. For more information see <https://www.amrindustryalliance.org/>.

Timeframe

1-3 years

Magnitude of potential impact

Medium

Likelihood

Virtually certain

Are you able to provide a potential financial impact figure?

Yes, a single figure estimate

Potential financial impact figure (currency)

100,000,000

Potential financial impact figure - minimum (currency)

Potential financial impact figure - maximum (currency)

Explanation of financial impact

Financial impact based on cost of remediation at owned and supplier sites. Remediation could be a technical fix or exiting the supplier or the product.

Primary response to risk

Direct operations
Increase capital expenditure

Description of response

Pfizer completed environmental risk assessments of antibiotic discharges at internal manufacturing sites and is nearing completion of assessments of all of our antibiotic suppliers globally. These assessments indicate that good practices are being followed at many sites. Where warranted, action plans are being developed and implemented to mitigate risk.

Cost of response

100,000,000

Explanation of cost of response

Represents the cost of remediation for owned and supplier sites or the cost to exit a supplier and/or product

W4.3

(W4.3) Have you identified any water-related opportunities with the potential to have a substantive financial or strategic impact on your business?

Yes, we have identified opportunities, and some/all are being realized

W4.3a

(W4.3a) Provide details of opportunities currently being realized that could have a substantive financial or strategic impact on your business.

Type of opportunity

Efficiency

Primary water-related opportunity

Improved water efficiency in operations

Company-specific description & strategy to realize opportunity

Pfizer established a public resource efficiency goal targeting a 5% reduction in water withdrawal by 5% by 2020 from our 2012 baseline. Pfizer requires medium and large sites (based on energy use) to maintain site master plans that identify opportunities to reduce their environmental footprint. Sites are expected to set annual performance targets and to identify, prioritize and implement water conservation projects to offset increases due to increased production. Project information is entered into a global database where it is monitored by sustainability champions at the site, business and global level. Progress is reported to business leadership quarterly.

Estimated timeframe for realization

1 to 3 years

Magnitude of potential financial impact

Low

Are you able to provide a potential financial impact figure?

Yes, a single figure estimate

Potential financial impact figure (currency)

142,000

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact

Pfizer's progress towards this goal is reported in the company's Annual Review. As of the end of 2019 Pfizer is now withdrawing 14% less water per annum than our 2012

baseline year, even as production has increased at our internal sites. Savings are related to a reduction in water and wastewater treatment costs. In 2019, Pfizer achieved an annual savings of approximately \$142,000 (112,400 cubic meters of water) as a result of water conservation projects. The potential financial impact represents potential annual savings from the implementation of new conservation projects.

W5. Facility-level water accounting

W5.1

(W5.1) For each facility referenced in W4.1c, provide coordinates, water accounting data, and a comparison with the previous reporting year.

Facility reference number

Facility 1

Facility name (optional)

KAEC

Country/Area & River basin

Saudi Arabia

Other, please specify

Red Sea

Latitude

21.627098

Longitude

39.136095

Located in area with water stress

Yes

Total water withdrawals at this facility (megaliters/year)

15.7

Comparison of total withdrawals with previous reporting year

Much lower

Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

Withdrawals from brackish surface water/seawater

0

Withdrawals from groundwater - renewable

0

Withdrawals from groundwater - non-renewable

0

Withdrawals from produced/entrained water

0

Withdrawals from third party sources

15.7

Total water discharges at this facility (megaliters/year)

9.5

Comparison of total discharges with previous reporting year

Much lower

Discharges to fresh surface water

0

Discharges to brackish surface water/seawater

0

Discharges to groundwater

0

Discharges to third party destinations

9.5

Total water consumption at this facility (megaliters/year)

6.2

Comparison of total consumption with previous reporting year

About the same

Please explain

The site's 2019 water withdrawal decreased by 35% compared to 2018. The site was being commissioned in 2018, requiring significantly more water to be used for equipment cleaning. Additionally, the site replaced its water softener with a smaller model, further reducing the site's water withdrawal.

W5.1a

(W5.1a) For the facilities referenced in W5.1, what proportion of water accounting data has been externally verified?

Water withdrawals – total volumes

% verified

Not verified

Water withdrawals – volume by source

% verified

Not verified

Water withdrawals – quality

% verified

Not verified

Water discharges – total volumes

% verified

Not verified

Water discharges – volume by destination

% verified

Not verified

Water discharges – volume by treatment method

% verified

Not verified

Water discharge quality – quality by standard effluent parameters

% verified

Not verified

Water discharge quality – temperature

% verified

Not verified

Water consumption – total volume

% verified

Not verified

Water recycled/reused

% verified

Not verified

W6. Governance

W6.1

(W6.1) Does your organization have a water policy?

Yes, we have a documented water policy that is publicly available

W6.1a

(W6.1a) Select the options that best describe the scope and content of your water policy.

	Scope	Content	Please explain
Row 1	Company-wide	Description of business dependency on water Description of business impact on water Reference to international standards and widely-recognized water initiatives Company water targets and goals Commitment to align with public policy initiatives, such as the SDGs Commitments beyond regulatory compliance Commitment to stakeholder awareness and education Commitment to water stewardship and/or collective action Acknowledgement of the human right to water and sanitation Recognition of environmental linkages, for example, due to climate change	Covered by Pfizer's publicly available EHS Policy, environmental sustainability goals and the Water Use page of our global website. Although not a formal member, Pfizer's approach is aligned with the UN Global Compact Water Mandate and uses the six core elements as guideposts for our Water Sustainability Program. We require facilities to track water use, report performance against reduction targets, and support community efforts during drought conditions. Pfizer has taken a leading role in the AMR Industry Alliance by spearheading its manufacturing working group which developed a manufacturing framework adopted by Roadmap signatory companies together with their suppliers. The group has published risk-based, science-based discharge concentrations. The group driving implementation of the environmental framework for manufacturing operations focused on wastewater discharge and waste management good practices to minimize releases of antibiotics to the environment.

W6.2

(W6.2) Is there board level oversight of water-related issues within your organization?

Yes

W6.2a

(W6.2a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for water-related issues.

Position of individual	Please explain
Board-level committee	The Regulatory & Compliance Committee (RCC) of the Board of Directors receives reports on key risks, including risks related to climate change, from the Pfizer Global Supply (PGS) Quality & Compliance Committee (PGS QCC)
Board-level committee	As reflected in its charter, one of the responsibilities of the Governance & Sustainability Committee (formerly the Governance Committee until 2019) is to maintain an informed status on Company issues related to corporate social responsibility, sustainability, philanthropy, and the Company's participation and visibility as a global corporate citizen. In 2019, during its annual update on corporate social responsibility, the Committee discussed Pfizer's environmental sustainability initiatives and position on climate change with management.
Board-level committee	Pfizer's Enterprise Risk Management (ERM) program provides a framework for risk identification and management of significant risks, including risks related to climate change and the long-term sustainability of the business. Each risk is assigned to a member or members, as appropriate, of our Executive Leadership Team. ERM is conducted at the direction of Legal, and the Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program.
Chief Executive Officer (CEO)	The PGS QCC reports key risks, including those related to climate change to the Executive Compliance Committee (ECC) of Pfizer's Executive Leadership Team, including the CEO.

W6.2b

(W6.2b) Provide further details on the board's oversight of water-related issues.

	Frequency that water-related issues are a scheduled agenda item	Governance mechanisms into which water-related issues are integrated	Please explain
Row 1	Scheduled - some meetings	Monitoring implementation and performance Reviewing and guiding risk management policies Reviewing and guiding strategy Reviewing and guiding corporate responsibility strategy	<p>The Audit Committee (AC) of the Board of Directors has primary responsibility for overseeing Pfizer's Enterprise Risk Management program. The Regulatory and Compliance Committee (RCC) of the Board also joins the ERM meeting with AC. The ERM program provides a framework for risk identification and management, which includes water-related risks.</p> <p>The Pfizer Global Supply Quality and Compliance Committee (PGS QCC) reports priority risks, including risks related to climate change, to the RCC.</p> <p>The Governance & Sustainability Committee</p>

			<p>maintains an informed status of Environmental, Social, Governance (ESG) related matters, which includes Pfizer's climate action and environmental sustainability program and goals.</p> <p>The CEO is responsible, in his capacity as CEO and member of the Board and Executive Leadership Team, for approving environmental sustainability-related public goals.</p>
--	--	--	--

W6.3

(W6.3) Provide the highest management-level position(s) or committee(s) with responsibility for water-related issues (do not include the names of individuals).

Name of the position(s) and/or committee(s)

Chief Financial Officer (CFO)

Responsibility

Both assessing and managing water-related risks and opportunities

Frequency of reporting to the board on water-related issues

Annually

Please explain

The CFO & Executive Vice President, Global Supply, leads Pfizer's manufacturing division and serves as the "risk owner" for the company's natural events risk category. Product manufacturing, managed by Pfizer's Global Supply division (PGS), accounts for 87% of the company's water withdrawal. Environmental sustainability has been integrated into the overarching PGS strategy and water withdrawal is monitored as a key performance indicator. Performance is included in a monthly dashboard reviewed by the CFO & EVP.

Name of the position(s) and/or committee(s)

Sustainability committee

Responsibility

Other, please specify

Establishing next generation environmental sustainability goals

Frequency of reporting to the board on water-related issues

Not reported to board

Please explain

In 2019, Pfizer established a Climate Action & Sustainability Executive Leadership sponsor team to oversee the Climate & Sustainability ERM risk and opportunity action plan which includes development of the next generation environmental sustainability strategy and public goals taking the company to 2030. The senior leaders responsible for leading the strategy and goal development process included members from EHS, Engineering, Compliance, Procurement, R&D, Corporate Affairs and Strategy & Innovation. Strategy and goals are ultimately approved by the ELT sponsor team and the CEO.

W6.4

(W6.4) Do you provide incentives to C-suite employees or board members for the management of water-related issues?

	Provide incentives for management of water-related issues	Comment
Row 1	No, and we do not plan to introduce them in the next two years	

W6.5

(W6.5) Do you engage in activities that could either directly or indirectly influence public policy on water through any of the following?

- Yes, trade associations
- Yes, funding research organizations
- Yes, other

W6.5a

(W6.5a) What processes do you have in place to ensure that all of your direct and indirect activities seeking to influence policy are consistent with your water policy/water commitments?

Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large in an effort to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups. However, Pfizer works in good faith with these organizations to make its position on climate change and other environmental issues known.

REF: <https://www.pfizer.com/purpose/contributions-partnerships/political-partnerships>

Information related to criteria used for third party funding may be found at:
http://www.pfizer.com/files/third_party_funding_criteria.pdf

W6.6

(W6.6) Did your organization include information about its response to water-related risks in its most recent mainstream financial report?

Yes (you may attach the report - this is optional)

 pfizer-2019-annual-review.pdf

W7. Business strategy

W7.1

(W7.1) Are water-related issues integrated into any aspects of your long-term strategic business plan, and if so how?

	Are water-related issues integrated?	Long-term time horizon (years)	Please explain
Long-term business objectives	Yes, water-related issues are integrated	11-15	Water-related risks are assessed at the site level as part of business continuity programs. Any risks identified through these annual assessments are addressed in site-specific business continuity plans and capital planning processes as required. The external scientific understanding of risks associated with pharmaceuticals in the environment (PIE) continues to evolve and therefore long-term approaches to risk management are also evolving. We continue to engage our stakeholders including industry groups, the scientific community, regulatory agencies, patient groups and nongovernmental organizations to advance the knowledge of PIE.
Strategy for achieving long-term objectives	Yes, water-related issues are integrated	11-15	Water-related risks are assessed at the site level as part of business continuity programs. Any risks identified through these annual assessments are addressed in site-specific business continuity plans and capital planning as required. The external scientific understanding of risks associated with pharmaceuticals in the environment (PIE) continues to evolve and therefore long-term approaches to risk management are also evolving. We continue to engage our stakeholders including industry groups, the scientific community, regulatory agencies, patient groups and nongovernmental organizations to advance the knowledge of PIE.

Financial planning	Yes, water-related issues are integrated	5-10	Water-related risks are assessed at the site level as part of business continuity programs. Any risks identified through these annual assessments are addressed in site-specific business continuity plans and capital planning as required. The external scientific understanding of risks, and any associated risk mitigation costs, associated with pharmaceuticals in the environment (PIE) continues to evolve and therefore long-term approaches to risk management are also evolving. We continue to engage our stakeholders including industry groups, the scientific community, regulatory agencies, patient groups and nongovernmental organizations to advance the knowledge of PIE.
--------------------	--	------	---

W7.2

(W7.2) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?

Row 1

Water-related CAPEX (+/- % change)

0

Anticipated forward trend for CAPEX (+/- % change)

0

Water-related OPEX (+/- % change)

0

Anticipated forward trend for OPEX (+/- % change)

0

Please explain

Capital and operating expenditures have remained relatively flat across the organization. Water costs represent approximately 1% of Pfizer's CAPEX spend and less than 1% of OPEX spend.

W7.3

(W7.3) Does your organization use climate-related scenario analysis to inform its business strategy?

Use of climate-related scenario analysis	Comment
--	---------

Row 1	No, but we anticipate doing so within the next two years	Pfizer is currently working with specialist vendors to perform a predictive analysis on global climate change risk applicable to critical Pfizer sites/assets. The output of the predictive analysis will support inclusion of climate-related scenario analysis into the business strategy. Based on this review, we expect that we will take a closer look at water related risks especially associated with physical risks. All Pfizer sites currently identified with water related risks could potentially have amplified risks from the changing climate.
-------	--	---

W7.4

(W7.4) Does your company use an internal price on water?

Row 1

Does your company use an internal price on water?

No, but we are currently exploring water valuation practices

Please explain

Pfizer is exploring the use of an internal price on water and will implement if determined to be beneficial to progressing conservation efforts.

W8. Targets

W8.1

(W8.1) Describe your approach to setting and monitoring water-related targets and/or goals.

	Levels for targets and/or goals	Monitoring at corporate level	Approach to setting and monitoring targets and/or goals
Row 1	Company-wide targets and goals Business level specific targets and/or goals Site/facility specific targets and/or goals	Targets are monitored at the corporate level Goals are monitored at the corporate level	<p>Pfizer's water strategy includes the development and execution of a dual track program. Track 1 aims to support sites through onsite assessment and guidance in meeting the company's 2020 Environmental Sustainability Goals, including setting site- and business-unit level annual and short term (< 5 year) targets. Track 2 aims to assess and reduce potential water related business risks at sites located in areas preliminarily identified as water stressed. Both tracks support an increased focus on water conservation projects.</p> <p>To support these efforts in 2015 Pfizer established a public goal to reduce water withdrawal excluding non-contact cooling water 5% by 2020 from a 2012 baseline. Progress is tracked quarterly for our manufacturing sites (80% of</p>

			footprint) as an indicator of overall performance and annually for all sites within Pfizer's operational control. As of the end of 2019, Pfizer has achieved a 14% reduction in water withdrawal compared to our 2012 baseline. Track 2 is assessed by annual completion of water scarcity risk assessment process.
--	--	--	---

W8.1a

(W8.1a) Provide details of your water targets that are monitored at the corporate level, and the progress made.

Target reference number

Target 1

Category of target

Water withdrawals

Level

Company-wide

Primary motivation

Reduced environmental impact

Description of target

Pfizer is committed to sustainable business. We take an entrepreneurial approach to sustainability practices to help produce measurable value for society and our business by reducing our reliance on energy and water and looking for innovative ways to better manage waste. We have established a public goal to reduce water withdrawal excluding non-contact cooling water 5% by 2020 from a 2012 baseline. We plan to announce our next generation environmental sustainability goals in early 2021.

Quantitative metric

Absolute reduction in total water withdrawals

Baseline year

2012

Start year

2015

Target year

2020

% of target achieved

100

Please explain

Our performance to date has exceeded our 2020 goal, however, we have not declared completion yet as Pfizer is planning the divestiture of its Upjohn business in 2020 and will be re-baselining our footprint as a result.

W8.1b

(W8.1b) Provide details of your water goal(s) that are monitored at the corporate level and the progress made.

Goal

Engagement with suppliers to help them improve water stewardship

Level

Company-wide

Motivation

Reduced environmental impact

Description of goal

Pfizer is committed to reducing the environmental impact of our supply network. We collect both qualitative and quantitative sustainability performance information from key suppliers. In 2015 Pfizer adopted a public goal that by 2020 100% of key suppliers will manage their environmental impacts through effective sustainability programs.

Baseline year

2016

Start year

2015

End year

2020

Progress

In 2019, 88% of our baseline group of key suppliers reported having sustainability programs in place.

Goal

Engagement with suppliers to reduce the water-related impact of supplied products

Level

Company-wide

Motivation

Reduced environmental impact

Description of goal

Pfizer is committed to reducing the environmental impact of our supply network. We collect both qualitative and quantitative sustainability performance information from key suppliers. In 2015 Pfizer adopted a public goal that by 2020 90% of key suppliers will institute reduction goals for greenhouse gas (GHG) emissions, waste disposal and water withdrawal.

Baseline year

2016

Start year

2015

End year

2020

Progress

In 2019, 49% of our baseline group of key suppliers reported having reduction goals in place for GHG emissions, waste disposal, and water withdrawal.

W9. Verification

W9.1

(W9.1) Do you verify any other water information reported in your CDP disclosure (not already covered by W5.1a)?

No, we do not currently verify any other water information reported in our CDP disclosure

W10. Sign off

W-FI

(W-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.

W10.1

(W10.1) Provide details for the person that has signed off (approved) your CDP water response.

	Job title	Corresponding job category
Row 1	Chief Financial Officer and Executive Vice President, Global Supply	Chief Financial Officer (CFO)

W10.2

(W10.2) Please indicate whether your organization agrees for CDP to transfer your publicly disclosed data on your impact and risk response strategies to the CEO Water Mandate's Water Action Hub [applies only to W2.1a (response to impacts), W4.2 and W4.2a (response to risks)].

Yes

SW. Supply chain module

SW0.1

(SW0.1) What is your organization's annual revenue for the reporting period?

	Annual revenue
Row 1	51,750,000,000

SW0.2

(SW0.2) Do you have an ISIN for your organization that you are willing to share with CDP?

Yes

SW0.2a

(SW0.2a) Please share your ISIN in the table below.

	ISIN country code	ISIN numeric identifier (including single check digit)
Row 1	US	7170811035

SW1.1

(SW1.1) Could any of your facilities reported in W5.1 have an impact on a requesting CDP supply chain member?

No, CDP supply chain members do not buy goods or services from facilities listed in W5.1

SW1.2

(SW1.2) Are you able to provide geolocation data for your facilities?

	Are you able to provide geolocation data for your facilities?	Comment
Row 1	Yes, for all facilities	Pfizer has geolocation information available for all facilities but is only providing the data relevant to requesting supply chain members.

SW1.2a

(SW1.2a) Please provide all available geolocation data for your facilities.

Identifier	Latitude	Longitude	Comment
Kalamazoo	42.289482	-85.578427	Providing geolocation data for facilities relevant to CDP Supply chain members.
Toluca	32.366486	-85.578427	Providing geolocation data for facilities relevant to CDP Supply chain members.

SW2.1

(SW2.1) Please propose any mutually beneficial water-related projects you could collaborate on with specific CDP supply chain members.

SW2.2

(SW2.2) Have any water projects been implemented due to CDP supply chain member engagement?

No

SW3.1

(SW3.1) Provide any available water intensity values for your organization's products or services.

Submit your response

In which language are you submitting your response?

English

Please confirm how your response should be handled by CDP

	I am submitting to	Public or Non-Public Submission	Are you ready to submit the additional Supply Chain Questions?
I am submitting my response	Investors Customers	Public	Yes, submit Supply Chain Questions now